more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

Top 32% (79 out of 250)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

by Zacks Equity Research Published on October 06,2023

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

by Zacks Equity Research Published on October 06,2023

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.

pharmaceuticals

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

by Zacks Equity Research Published on October 06,2023

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

by Zacks Equity Research Published on October 06,2023

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data

by Zacks Equity Research Published on October 05,2023

Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research Published on October 04,2023

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research Published on October 04,2023

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

by Zacks Equity Research Published on October 03,2023

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

by Zacks Equity Research Published on October 03,2023

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

by Zacks Equity Research Published on October 03,2023

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

by Zacks Equity Research Published on October 03,2023

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

pharmaceuticals

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research Published on September 29,2023

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

by Zacks Equity Research Published on September 29,2023

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

by Zacks Equity Research Published on September 29,2023

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research Published on September 28,2023

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

biotechs

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

by Zacks Equity Research Published on September 28,2023

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research Published on September 28,2023

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.